PUBLISHER: 360iResearch | PRODUCT CODE: 1316928

PUBLISHER: 360iResearch | PRODUCT CODE: 1316928

Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

PUBLISHED: June 12, 2023

PAGES: 181 Pages

DELIVERY TIME: 1-2 business days

SELECT AN OPTION

The Global Biosimilar Monoclonal Antibodies Market is forecasted to grow significantly, with a projected USD 7,694.25 million in 2023 at a CAGR of 23.17% and expected to reach a staggering USD 33,141.44 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Biosimilar Monoclonal Antibodies Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Biosimilar Monoclonal Antibodies Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across Abciximab, Adalimumab, Bevacizumab, Infliximab, Rituximab, and Trastuzumab. The Trastuzumab is projected to witness significant market share during forecast period.

Based on Application, market is studied across Diagnostic, Protein Purification, and Therapeutic. The Diagnostic is further studied across MABs in Biochemical Analysis and MABs in Diagnostic Imaging. The MABs in Biochemical Analysis is further studied across Cancers, Hormonal Disorders, Infectious Diseases, and Pregnancy. The MABs in Diagnostic Imaging is further studied across Atherosclerosis, Bacterial Infections, Cancers, Cardiovascular Diseases, and Deep Vein Thrombosis. The Therapeutic is further studied across MABs as Direct Therapeutic Agents and MABs as Targeting Agents in Therapy. The Therapeutic is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Biosimilar Monoclonal Antibodies Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biosimilar Monoclonal Antibodies Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilar Monoclonal Antibodies Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilar Monoclonal Antibodies Market?

4. What is the competitive strategic window for opportunities in the Global Biosimilar Monoclonal Antibodies Market?

5. What are the technology trends and regulatory frameworks in the Global Biosimilar Monoclonal Antibodies Market?

6. What is the market share of the leading vendors in the Global Biosimilar Monoclonal Antibodies Market?

7. What modes and strategic moves are considered suitable for entering the Global Biosimilar Monoclonal Antibodies Market?

Product Code: MRR-437D45957EA1

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Biosimilar Monoclonal Antibodies Market, by Drug Class, 2022 vs 2030
4.3. Biosimilar Monoclonal Antibodies Market, by Application, 2022 vs 2030
4.4. Biosimilar Monoclonal Antibodies Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
  - 5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
  - 5.1.1.3. Increasing healthcare expenditure in economies
- 5.1.2. Restraints
  - 5.1.2.1. Government regulations towards the absence of pre-analytical tests
- 5.1.3. Opportunities
  - 5.1.3.1. Rising number of inorganic strategies for the expansion of production facility
  - 5.1.3.2. Focus on R&D to introduce innovative product pipeline
- 5.1.4. Challenges
  - 5.1.4.1. Complexities associated with manufacturing processes
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Biosimilar Monoclonal Antibodies Market, by Drug Class

6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab

7. Biosimilar Monoclonal Antibodies Market, by Application

7.1. Introduction
7.2. Diagnostic
- 7.2.1. MABs in Biochemical Analysis
  - 7.2.1.1. Cancers
  - 7.2.1.2. Hormonal Disorders
  - 7.2.1.3. Infectious Diseases
  - 7.2.1.4. Pregnancy
- 7.2.2. MABs in Diagnostic Imaging
  - 7.2.2.1. Atherosclerosis
  - 7.2.2.2. Bacterial Infections
  - 7.2.2.3. Cancers
  - 7.2.2.4. Cardiovascular Diseases
  - 7.2.2.5. Deep Vein Thrombosis
7.3. Protein Purification
7.4. Therapeutic
- 7.4.1. MABs as Direct Therapeutic Agents
- 7.4.2. MABs as Targeting Agents in Therapy

8. Americas Biosimilar Monoclonal Antibodies Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Biosimilar Monoclonal Antibodies Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing

Product Code: MRR-437D45957EA1

LIST OF FIGURES

FIGURE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2022 VS 2030
FIGURE 3. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
FIGURE 5. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 6. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 7. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET DYNAMICS
FIGURE 8. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 15. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 5. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 12. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 13. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 15. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 21. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS , BY REGION, 2018-2030 (USD MILLION)
TABLE 27. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 29. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 51. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 54. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 55. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 56. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 83. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 86. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 87. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 88. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 89. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 92. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 93. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 94. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 101. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 137. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 156. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 162. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 168. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 174. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 180. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 192. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 195. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 196. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 197. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 210. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 216. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 219. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 220. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 221. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 222. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 225. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 226. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 227. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 246. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 264. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 282. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 283. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2022
TABLE 284. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET LICENSE & PRICING

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ